Gregory Piazza on The Effect of Enduring Risk Factors in Provoked VTE
Gregory Piazza, Director of the Vascular Medicine Section at Brigham and Women’s Hospital, shared on LinkedIn:
”What impact do the type and number of enduring risk factors have on the risk of recurrent venous thromboembolism in patients with an initial provoked event?
A subanalysis of our HI-PRO randomized controlled trials demonstrates just how important recognition of enduring risk is for shared decision making on extended secondary prevention.”
Read the full article here.
Article: Impact of enduring risk factors on efficacy and safety of extended anticoagulation for provoked venous thromboembolism: Post-hoc analysis of the HI-PRO trial
Authors: Mariana Pfeferman, Sina Rashedi, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison, Heather Hogan, Junyang Lou, John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, Samuel Z. Goldhaber, Behnood Bikdeli, Gregory Piazza on behalf of the HI-PRO Trial Investigators
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 25, 2026, 16:26Gemma Postil: AI Tools in Modern Health Research
-
Sep 25, 2026, 16:01Mostafa Hammam: When aPTT Correction Is Not the End
-
Sep 25, 2026, 15:50Adam Boruchov: Registration Is Open For The 2026 New England Hematologic Diseases Symposium
-
Sep 25, 2026, 15:23Bringing Hope and Treatment Access to Morocco’s Hemophilia Community – World Federation of Hemophilia
-
Sep 25, 2026, 15:22Alejandro González Veliz: Targeting Atherosclerosis Before the First Event
-
Sep 25, 2026, 15:00Sarah Richardson: Finding Strength Through Bleeding Disorders Advocacy
-
Sep 25, 2026, 14:54James Fildes: Modeling Device Related Thrombosis in Multi Organ Systems
-
Sep 25, 2026, 14:51Platelet Metabolic Reprogramming: How Cellular Energy Drives Thrombosis
-
Sep 25, 2026, 14:46Thomas Maxwell: From Hemophilia Shame to Strength – Walking for Bleeding Disorders